PMS-IPRATROPIUM SOLUTION

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

IPRATROPIUM BROMIDE

Pieejams no:

PHARMASCIENCE INC

ATĶ kods:

R03BB01

SNN (starptautisko nepatentēto nosaukumu):

IPRATROPIUM BROMIDE

Deva:

250MCG

Zāļu forma:

SOLUTION

Kompozīcija:

IPRATROPIUM BROMIDE 250MCG

Ievadīšanas:

INHALATION

Vienības iepakojumā:

20ML

Receptes veids:

Prescription

Ārstniecības joma:

ANTIMUSCARINICS ANTISPASMODICS

Produktu pārskats:

Active ingredient group (AIG) number: 0115643001; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2014-01-20

Produkta apraksts

PRODUCT MONOGRAPH
PMS-IPRATROPIUM
Ipratropium Bromide Nebulizer Solution
250 mcg/mL (0.025%) in 20 mL Bottles
BRONCHODILATOR
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montreal, Quebec
H4P 2T4
www.pharmascience.com
DATE OF REVISION:
May 11, 2017
CONTROL NO.: 204492
_pms-IPRATROPIUM Product Monograph Page 2 of 28_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..................................................... 3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL USE
................................................................................
3
CONTRAINDICATIONS
.....................................................................................................
3
WARNINGS AND PRECAUTIONS
....................................................................................
4
ADVERSE REACTIONS
......................................................................................................
7
DRUG INTERACTIONS
....................................................................................................
10
DOSAGE AND ADMINISTRATION
................................................................................
10
OVERDOSAGE
...................................................................................................................
11
ACTION AND CLINICAL
PHARMACOLOGY...............................................................
11
STORAGE AND STABILITY
............................................................................................
14
SPECIAL HANDLING INSTRUCTIONS
.........................................................................
15
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................... 15
PART II: SCIENTIFIC INFORMATION
..........................................................................
16
PHARMACEUTICAL INFORMATION
............................................................................
16
CLINICAL TRIALS
...........................